The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.634
Bid: 1.632
Ask: 1.664
Change: 0.005 (0.31%)
Spread: 0.032 (1.961%)
Open: 1.698
High: 1.70
Low: 1.634
Prev. Close: 1.629
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Aurora Investment Trust beats annual benchmark

Fri, 29th Apr 2022 19:34

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Aurora Investment Trust PLC - investment company - Net asset value total return for 2021 stands at 19.1%, compared to the benchmark, the FTSE All-Share Index, which returned 18.3%. As at December 31, net asset value per share increased 19% to 253.49 pence from 213.39p the same date a year prior.

----------

Honye Financial Services Ltd - Cayman Islands-based company seeking acquisitions in financial services and financial technology - For the six months ended January 31, pretax loss narrows to GBP75,430 from GBP345,241 the same period a year prior, due to lower administrative costs and one-off other income of GBP192,922 through directors Wanbao Xu and Yu Wing Xu waiving their unpaid salaries.

----------

Ceiba Investments Ltd - investment firm dedicated to investing in Cuba, with interests in the commercial and tourism real estate sectors - As at December 31, net asset value per share declines 18% to USD1.16 from USD1.41 the same date a year before.

----------

Neometals Ltd - London-based battery materials from upstream extraction and downstream processing - As at March 31, cash balance stands at AUD65.2 million. During the three month period, for the lithium-ion battery recycling project stage 2 refining trials are complete, and at the vanadium recovery project a feasibility study for the SSAB project has advanced during the quarter and is on-track for completion by the end of June.

----------

Riverstone Energy Ltd - energy investor - Net asset value per share as at March 31 is USD14.97, up 21% from the figure at the end of 2021, driven by stronger performances from portfolio firms Onyx, Centennial, Hammerhead and Enviva. Total invested capital stands at USD70 million, while realisations came up to USD66.6 million. As at March 31, portfolio has potential unfunded commitments at March 31 of USD13 million.

----------

AEX Gold Inc - Greenland-focused gold miner - For 2021, net loss widens to CAD24.7 million from CAD12.3 million the year before, as exploration and administrative expenses continued to rise, following the completion of the 2021 exploration programme at the Nalunaq project. Exploration was also conducted at the Vagar Ridge and Nanoq Gold targets.

----------

Sovereign Metals Ltd - Perth-based rutile exploration and development company focused in Malawi - At Kasiya project, mineral resource estimate is upgraded to 1.8 billion tonnes at 1.01% rutile and 1.32% graphite, equating to 18 million tonnes of contained rutile and 23 million tonnes of contained graphite. Company has started an updated scoping study to examine the impact of higher grades, increased production volumes and increased mine life. Looking ahead, demand for high-grade titanium dioxide feedstocks continued to remain strong.

----------

Acceler8 Ventures PLC - Jersey-based acquisitions company - For the nine months ended December 31, reports pretax loss of GBP383,783, reflecting operating expenses from professional services and listing expenses. Looking ahead, company does not expects to pay dividends in the "foreseeable future" at its current stage of development.

----------

Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - For 2021, pretax loss widens to GBP5.1 million from GBP2.1 million the year before, driven by a hike in finance costs to GBP2.6 million as a result of a repayment in principal and interest to settle the convertible loan facilities from Orgenesis Inc.

----------

Red Rock Resources PLC - gold explorer in Kenya and Australia, copper-cobalt in DRC - For the six months ended December 31, posts loss of GBP1.5 million, widening from GBP430,000 a year prior,as a result of higher administrative, project development and exploration expenses, following the completion of reverse circulation drill programmes in Kenya for gold and Congo for copper and cobalt.

----------

Caracal Gold PLC - gold producer with operations in East Africa - Says is making headway with three-phase operational plan is well underway at flagship Kilimapesa gold mine In Kenya, looks to increase gold production to 24,000 ounces per annum and improve efficiencies. Foe 2021, revenue up at GBP4.4 million from GBP1.0 million year before and pretax loss widens to GBP8.4 million from GBP836,000 in 2020.

----------

Sherborne Investors (Guernsey) C Ltd - funds set up with the specific policy of investing in one company, decided by investment manager Sherborne Investors Management LP, the investment vehicle of activist investor Edward Bramson - Posts net asset value per share as at December 31 at 82.93 pence per share, up 38% from 60.21p the same date a year before.

----------

Orosur Mining Inc - South American gold exploration and development company - For the third quarter ended March 31, net loss narrows to USD37,000 from USD1.2 million the same period a year prior, mainly due to a share-based compensation of USD41,000 compared to a charge of USD859,000.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

Read more
16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases.

Read more
14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections.

Read more
9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.

Read more
2 Feb 2024 10:44

IN BRIEF: Hemogenyx hails US patent application progress

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Read more
16 Jan 2024 11:13

Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

Read more
8 Jan 2024 10:56

Hemogenyx Pharmaceuticals completes process qualification run

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

Read more
28 Nov 2023 16:53

TRADING UPDATES: Upland Resources completes technical study at Sarawak

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Nov 2023 10:52

Hemogenyx shares up as says CBR platform a potential cancer treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said its chimeric based receptor platform could "potentially" be used to treat cancer and viral diseases.

Read more
15 Nov 2023 15:43

Hemogenyx Pharmaceuticals completes lentivirus re-manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said it has completed the re-manufacturing of an improved lentivirus devoid of splice variants.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Sep 2023 14:37

TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
18 Sep 2023 13:00

Hermogenyx shares soar on new partnership with Prevail Partners

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Read more
14 Sep 2023 14:31

Hemogenyx Pharma says US FDA accepts Hemo-Car-T clinical hold lift plan

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said the US Food & Drug Administration has accepted its plan to address concerns which sparked a clinical hold on its chimeric antigen receptor T-cell or Hemo-Car-T therapy.

Read more
8 Sep 2023 19:43

IN BRIEF: Hemogenyx Pharmaceuticals says patent number published

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for blood diseases - Says its patent application number "WO2023168292 Chimeric Bait Receptors and Uses Thereof" was published by the World Intellectual Property Organization on Thursday. Says it remains to be reviewed and approved by national patent authorities.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.